Universität zu Köln

Journal Article

Armand, Philippe, Engert, Andreas, Younes, Anas, Fanale, Michelle, Santoro, Armando ORCID: 0000-0003-1709-9492, Zinzani, Pier Luigi, Timmerman, John M., Collins, Graham P., Ramchandren, Radhakrishnan, Cohen, Jonathon B., De Boer, Jan Paul, Kuruvilla, John, Savage, Kerry J., Trneny, Marek, Shipp, Margaret A., Kato, Kazunobu, Sumbul, Anne, Farsaci, Benedetto ORCID: 0000-0001-8275-2561 and Ansell, Stephen M. (2018). Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J. Clin. Oncol., 36 (14). S. 1428 - 1450. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Armand, Philippe, Engert, Andreas, Younes, Anas, Lee, Hun Ju, Santoro, Armando, Zinzani, Pier Luigi, Timmerman, John M., Collins, Graham P., Ramchandren, Radhakrishnan, Cohen, Jonathon B., De Boer, Jan Paul, Savage, Kerry J., Kuruvilla, John, Trneny, Marek, Shipp, Margaret A., Sacchi, Mariana, Ansell, Anne Sumbuland Stephen M. and Ansell, Stephen M. (2018). Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Bishop, Michael R., Dickinson, Michael, Purtill, Duncan, Barba, Pere, Santoro, Armando, Hamad, Nada, Kato, Koji, Sureda, Anna, Greil, Richard, Thieblemont, Catherine, Morschhauser, Franck, Janz, Martin, Flinn, Ian W., Rabitsch, Werner, Kwong, Yok Lam, Kersten, Marie Jose, Minnema, Monique C., Holte, Harald, Chan, Esther Hian Li, Martinez-Lopez, Joaquin, Mueller, Antonia M. S., Maziarz, Richard T., McGuirk, Joseph P., Bachy, Emmanuel, Le Gouill, Steven, Dreyling, Martin, Harigae, Hideo, Bond, David A., Andreadis, Charalambos, McSweeney, Peter A., Kharfan-Dabaja, Mohamed A., Newsome, Simon, Degtyarev, Evgeny, Del Corral, Chris, Andreola, Giovanna, Masood, Aisha, Schuster, Stephen J., Jaeger, Ulrich, Borchmann, Peter and Westin, Jason R. (2021). Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study. Blood, 138. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Cohen, Jonathon B., Kuruvilla, John, Engert, Andreas, Ansell, Stephen M., Younes, Anas, Lee, Hun Ju, Trneny, Marek, Savage, Kerry J., Ramchandren, Radhakrishnan, Collins, Graham P., Zinzani, Pier Luigi, De Boer, Jan Paul, Shipp, Margaret A., Santoro, Armando, Timmerman, John M., Sacchi, Mariana, Sy, Oumar and Armand, Philippe (2018). Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Faivre, Sandrine J., Santoro, Armando ORCID: 0000-0003-1709-9492, Kelley, Robin Kate, Merle, Philippe, Gane, Ed, Douillard, Jean-Yves, Waldschmidt, Dirk, Mulcahy, Mary Frances, Costentin, Charlotte, Minguez, Beatriz ORCID: 0000-0002-7276-9666, Papappicco, Pasqua, Gueorguieva, Ivelina, Cleverly, Ann, Desaiah, Durisala, Lahn, Michael M., Ameryckx, Sophie, Benhadji, Karim A., Raymond, Eric and Giannelli, Gianluigi (2014). A phase 2 study of a novel transforming growth factor-beta (TGF-beta 1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC). J. Clin. Oncol., 32 (3). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Kim, Dong-Wan, Mehra, Ranee, Tan, Daniel S. W., Felip, Enriqueta, Chow, Laura Q. M., Camidge, D. Ross, Vansteenkiste, Johan, Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin, Liu, Geoffrey ORCID: 0000-0002-2603-7296, Santoro, Armando ORCID: 0000-0003-1709-9492, Sutradhar, Santosh, Li, Siyu, Szczudlo, Tomasz, Yovine, Alejandro and Shaw, Alice T. (2016). Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol., 17 (4). S. 452 - 464. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Kim, Dong-Wan, Mehra, Ranee, Tan, Daniel Shao-Weng, Felip, Enriqueta, Chow, Laura Quan Man, Camidge, D. Ross, Vansteenkiste, Johan F., Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin H., Liu, Geoffrey, Santoro, Armando ORCID: 0000-0003-1709-9492, Geraldes, Margarida, Boral, Anthony, Yovine, Alejandro Javier and Shaw, Alice Tsang (2014). Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Roemer, Margaretha G. M., Ligon, Azra H., Engert, Andreas, Younes, Anas, Santoro, Armando, Zinzani, Pier Luigi, Timmerman, John M., Ansell, Stephen, Armand, Philippe, Fanale, Michelle A., Ratanatharathorn, Voravit, Kuruvilla, John, Cohen, Jonathon B., Collins, Graham P., Savage, Kerry J., Trneny, Marek, Neuberg, Donna S., Redd, Robert A., Farsaci, Benedetto ORCID: 0000-0001-8275-2561, Kato, Kazunobu, Sumbul, Anne, Rodig, Scott J. and Shipp, Margaret A. (2016). Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade). Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Roemer, Margaretha G. M., Redd, Robert A., Cader, Fathima Zumla, Pak, Christine J., Abdelrahman, Sara, Ouyang, Jing, Sasse, Stephanie, Younes, Anas, Fanale, Michelle, Santoro, Armando ORCID: 0000-0003-1709-9492, Zinzani, Pier Luigi, Timmerman, John, Collins, Graham P., Ramchandren, Radhakrishnan, Cohen, Jonathon B., De Boer, Jan Paul, Kuruvilla, John, Savage, Kerry J., Trneny, Marek, Ansell, Stephen, Kato, Kazunobu, Farsaci, Benedetto ORCID: 0000-0001-8275-2561, Sumbul, Anne, Armand, Philippe, Neuberg, Donna S., Pinkus, Geraldine S., Ligon, Azra H., Rodig, Scott J. and Shipp, Margaret A. (2018). Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J. Clin. Oncol., 36 (10). S. 942 - 954. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Shaw, Alice, Mehra, Ranee, Tan, Daniel S. W., Felip, Enriqueta, Chow, Laura Q. M., Camidge, D. Ross, Vansteenkiste, Johan, Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin, Liu, Geoffrey, Santoro, Armando ORCID: 0000-0003-1709-9492, Geraldes, Margarida, Sen, Paramita, Boral, Anthony J., Yovine, Alejandro and Kim, Dong-Wan (2014). CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK plus ) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL. Neuro-Oncology, 16. CARY: OXFORD UNIV PRESS INC. ISSN 1523-5866

Shaw, Alice T., Kim, Dong-Wan, Mehra, Ranee, Tan, Daniel S. W., Felip, Enriqueta, Chow, Laura Q. M., Camidge, D. Ross, Vansteenkiste, Johan, Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin, Liu, Geoffrey ORCID: 0000-0002-2603-7296, Santoro, Armando ORCID: 0000-0003-1709-9492, Lau, Yvonne Y., Goldwasser, Meredith, Boral, Anthony L. and Engelman, Jeffrey A. (2014). Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer. N. Engl. J. Med., 370 (13). S. 1189 - 1198. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Tan, Daniel Shao-Weng, Shaw, Alice Tsang, Mehra, Ranee, Felip, Enriqueta, Chow, Laura Quan Man, Camidge, D. Ross, Vansteenkiste, Johan F., Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin H., Liu, Geoffrey, Santoro, Armando ORCID: 0000-0003-1709-9492, Geraides, Margarida, Boral, Anthony, Yovine, Alejandro Javier and Kim, Dong-Wan (2014). Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) NSCLC: Subgroup analysis of the ASCEND-1 trial. J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Timmerman, John M., Engert, Andreas, Younes, Anas, Santoro, Armando, Armand, Philippe, Fanale, Michelle A., Collins, Graham P., Ratanatharathorn, Voravit, Kuruvilla, John, Cohen, Jonathon B., Savage, Kerry J., Trneny, Marek, De Boer, Jan Paul, Shipp, Margaret A., Rodig, Scott J., Kato, Kazunobu, Sumbul, Anne and Ansell, Stephen (2016). Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Younes, Anas, Santoro, Armando ORCID: 0000-0003-1709-9492, Shipp, Margaret, Zinzani, Pier Luigi, Timmerman, John M., Ansell, Stephen, Armand, Philippe, Fanale, Michelle, Ratanatharathorn, Voravit, Kuruvilla, John, Cohen, Jonathon B., Collins, Graham ORCID: 0000-0002-8803-4234, Savage, Kerry J., Trneny, Marek ORCID: 0000-0002-6952-6073, Kato, Kazunobu, Farsaci, Benedetto ORCID: 0000-0001-8275-2561, Parker, Susan M., Rodig, Scott, Roemer, Margaretha G. M., Ligon, Azra H. and Engert, Andreas (2016). Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol., 17 (9). S. 1283 - 1295. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Younes, Anas, Santoro, Armando, Zinzani, Pier Luigi, Timmerman, John, Ansell, Stephen Maxted, Armand, Philippe, Fanale, Michelle A., Ratanatharathorn, Voravit, Kuruvilla, John, Cohen, Jonathon Brett, Collins, Graham P., Savage, Kerry J., Trneny, Marek, Kato, Kazunobu, Farsaci, Benedetto ORCID: 0000-0001-8275-2561, Parker, Susan M., Rodig, Scott J., Shipp, Margaret Ann and Engert, Andreas (2016). Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) A phase 2 study. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755